Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies
Parkinson’s disease is one of the main reasons for neurological consultation in Spain. Due to the nature of the disease, it impacts patients, families, and caregivers. Parkinson’s disease is a degenerative disease with no cure, although second-line therapies have recently improved the quality of lif...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2020/9106026 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553240651104256 |
|---|---|
| author | Elisa Gomez-Inhiesto María Teresa Acaiturri-Ayesta Iker Ustarroz-Aguirre Diana Camahuali Maider Urtaran-Laresgoiti Marisol Basabe-Aldecoa Roberto Nuño-Solinís Elena Urizar |
| author_facet | Elisa Gomez-Inhiesto María Teresa Acaiturri-Ayesta Iker Ustarroz-Aguirre Diana Camahuali Maider Urtaran-Laresgoiti Marisol Basabe-Aldecoa Roberto Nuño-Solinís Elena Urizar |
| author_sort | Elisa Gomez-Inhiesto |
| collection | DOAJ |
| description | Parkinson’s disease is one of the main reasons for neurological consultation in Spain. Due to the nature of the disease, it impacts patients, families, and caregivers. Parkinson’s disease is a degenerative disease with no cure, although second-line therapies have recently improved the quality of life of patients in advanced stages. The aim of this study was to analyse the costs of the following therapies: deep brain stimulation (DBS), continuous duodenal levodopa/carbidopa infusion (CDLCI), and continuous subcutaneous apomorphine infusion (CSAI). The methodology used was based on real-world data obtained from an integrated healthcare organization in the Basque Country from 2016 to 2018. This bottom-up retrospective approach only took into account the healthcare perspective. The results revealed the annual cost over 3 years and the projected cost for an additional 2 years. The total costs for 5 years of treatment were as follows: €53,217 for DBS, €208,163 for CDLCI, and €170,591 for CSAI. These costs are in line with those found in the available literature on the subject. Additionally, the analysis provided details of the different costs incurred during intervention with the therapies and compared the costs to those reported in other studies. |
| format | Article |
| id | doaj-art-11ea4464744a4495917e83283371d94e |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-11ea4464744a4495917e83283371d94e2025-02-03T05:54:26ZengWileyParkinson's Disease2090-80832042-00802020-01-01202010.1155/2020/91060269106026Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line TherapiesElisa Gomez-Inhiesto0María Teresa Acaiturri-Ayesta1Iker Ustarroz-Aguirre2Diana Camahuali3Maider Urtaran-Laresgoiti4Marisol Basabe-Aldecoa5Roberto Nuño-Solinís6Elena Urizar7Dirección Económico-Financiera, Hospital Universitario Cruces—OSI Ezkerraldea Enkarterri Cruces, Barakaldo, Biscay, SpainDirección Económico-Financiera, Hospital Universitario Cruces—OSI Ezkerraldea Enkarterri Cruces, Barakaldo, Biscay, SpainDirección Económico-Financiera, Hospital Universitario Cruces—OSI Ezkerraldea Enkarterri Cruces, Barakaldo, Biscay, SpainDeusto Business School Health, University of Deusto, Bilbao, SpainDeusto Business School Health, University of Deusto, Bilbao, SpainDeusto Business School Health, University of Deusto, Bilbao, SpainDeusto Business School Health, University of Deusto, Bilbao, SpainDeusto Business School Health, University of Deusto, Bilbao, SpainParkinson’s disease is one of the main reasons for neurological consultation in Spain. Due to the nature of the disease, it impacts patients, families, and caregivers. Parkinson’s disease is a degenerative disease with no cure, although second-line therapies have recently improved the quality of life of patients in advanced stages. The aim of this study was to analyse the costs of the following therapies: deep brain stimulation (DBS), continuous duodenal levodopa/carbidopa infusion (CDLCI), and continuous subcutaneous apomorphine infusion (CSAI). The methodology used was based on real-world data obtained from an integrated healthcare organization in the Basque Country from 2016 to 2018. This bottom-up retrospective approach only took into account the healthcare perspective. The results revealed the annual cost over 3 years and the projected cost for an additional 2 years. The total costs for 5 years of treatment were as follows: €53,217 for DBS, €208,163 for CDLCI, and €170,591 for CSAI. These costs are in line with those found in the available literature on the subject. Additionally, the analysis provided details of the different costs incurred during intervention with the therapies and compared the costs to those reported in other studies.http://dx.doi.org/10.1155/2020/9106026 |
| spellingShingle | Elisa Gomez-Inhiesto María Teresa Acaiturri-Ayesta Iker Ustarroz-Aguirre Diana Camahuali Maider Urtaran-Laresgoiti Marisol Basabe-Aldecoa Roberto Nuño-Solinís Elena Urizar Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies Parkinson's Disease |
| title | Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies |
| title_full | Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies |
| title_fullStr | Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies |
| title_full_unstemmed | Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies |
| title_short | Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies |
| title_sort | direct cost of parkinson s disease a real world data study of second line therapies |
| url | http://dx.doi.org/10.1155/2020/9106026 |
| work_keys_str_mv | AT elisagomezinhiesto directcostofparkinsonsdiseasearealworlddatastudyofsecondlinetherapies AT mariateresaacaiturriayesta directcostofparkinsonsdiseasearealworlddatastudyofsecondlinetherapies AT ikerustarrozaguirre directcostofparkinsonsdiseasearealworlddatastudyofsecondlinetherapies AT dianacamahuali directcostofparkinsonsdiseasearealworlddatastudyofsecondlinetherapies AT maiderurtaranlaresgoiti directcostofparkinsonsdiseasearealworlddatastudyofsecondlinetherapies AT marisolbasabealdecoa directcostofparkinsonsdiseasearealworlddatastudyofsecondlinetherapies AT robertonunosolinis directcostofparkinsonsdiseasearealworlddatastudyofsecondlinetherapies AT elenaurizar directcostofparkinsonsdiseasearealworlddatastudyofsecondlinetherapies |